Ariel Investments LLC Has $214.75 Million Stock Position in Charles River Laboratories International, Inc. $CRL

Ariel Investments LLC grew its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 28.6% during the second quarter, Holdings Channel.com reports. The firm owned 1,415,348 shares of the medical research company’s stock after acquiring an additional 314,572 shares during the quarter. Charles River Laboratories International accounts for about 2.4% of Ariel Investments LLC’s portfolio, making the stock its 14th biggest position. Ariel Investments LLC’s holdings in Charles River Laboratories International were worth $214,751,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in the business. Charles Schwab Investment Management Inc. grew its position in Charles River Laboratories International by 4.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 577,322 shares of the medical research company’s stock valued at $86,899,000 after purchasing an additional 24,347 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Charles River Laboratories International by 77.0% during the 1st quarter. Deutsche Bank AG now owns 411,419 shares of the medical research company’s stock worth $61,927,000 after buying an additional 178,927 shares during the last quarter. National Bank of Canada FI grew its holdings in shares of Charles River Laboratories International by 42.5% in the 1st quarter. National Bank of Canada FI now owns 33,987 shares of the medical research company’s stock valued at $5,116,000 after acquiring an additional 10,132 shares in the last quarter. Townsquare Capital LLC increased its position in shares of Charles River Laboratories International by 401.8% in the first quarter. Townsquare Capital LLC now owns 12,775 shares of the medical research company’s stock valued at $1,923,000 after acquiring an additional 10,229 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Charles River Laboratories International in the first quarter valued at about $3,739,000. Institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Argus set a $200.00 price objective on Charles River Laboratories International in a research note on Monday, November 17th. Barclays boosted their target price on shares of Charles River Laboratories International from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. Robert W. Baird raised shares of Charles River Laboratories International from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $178.00 to $199.00 in a research report on Thursday, November 6th. William Blair raised shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research report on Monday, October 6th. Finally, Wall Street Zen lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average price target of $190.86.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $186.00 on Wednesday. The stock has a market cap of $9.15 billion, a PE ratio of -119.23, a P/E/G ratio of 6.61 and a beta of 1.63. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.37. The firm has a 50-day moving average of $176.23 and a 200-day moving average of $162.46. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $202.72.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $2.32 by $0.11. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $990.43 million. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. Charles River Laboratories International’s quarterly revenue was down .5% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.59 EPS. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).